Category: 110256-15-0

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.110256-15-0,5-Cyclopropylisoxazole-3-carboxylic acid,as a common compound, the synthetic route is as follows.

110256-15-0, To a solution of 5-cyclopropylisoxazole-3-carboxylic acid (650 mg, 4.24 mmol) in DMF (2 mL) were added N,O-dimethylhydroxylamine hydrochloride (497 mg, 5.09 mmol), DIPEA (2.22 mL, 12.73 mmol) and 1-propanephosphonic anhydride (3.75 mL, 6.37 mmol) at room temperature. The reaction mixture was stirred at the same temperature for 16 h. The reaction mixture was diluted with water and extracted twice with ethyl acetate (20 mL). The combined organic layer was dried over Na2SO4 and evaporated under reduced pressure to dryness. The crude product was purified by flash column chromatography (Column: 24g silica; Solvent run: 0-50% EtOAc in pet ether). The product was eluted at 30% EtOAc in pet ether to yield 5-cyclopropyl-N-methoxy-N- methylisoxazole-3-carboxamide (450 mg, 2.16 mmol, 50.8 % yield). LCMS: m/z, 197.1 (M+H); rt 1.07 min; Column: Waters Acquity UPLC BEH C18 (2.1 x 50 mm) 1.7 mm, Mobile phase A: 10 mM ammonium acetate:acetonitrile (95:5); Mobile phase B: 10 mM ammonium acetate:acetonitrile (5:95), Gradient = 20-90 % B over 1.1 minute, then a 0.6 minute hold at 90 % B; Temperature: 50 C; Flow rate: 0.7 mL/min; Detection: UV at 220 nm

As the paragraph descriping shows that 110256-15-0 is playing an increasingly important role.

Reference£º
Patent; BRISTOL-MYERS SQUIBB COMPANY; VELAPARTHI, Upender; CHUPAK, Louis S.; DARNE, Chetan Padmakar; DING, Min; GENTLES, Robert G.; HUANG, Yazhong; KAMBLE, Manjunatha Narayana Rao; MARTIN, Scott W.; MANNOORI, Raju; MCDONALD, Ivar M.; OLSON, Richard E.; RAHAMAN, Hasibur; JALAGAM, Prasada Rao; ROY, Saumya; TONUKUNURU, Gopikishan; VELAIAH, Sivasudar; WARRIER, Jayakumar Sankara; ZHENG, Xiaofan; TOKARSKI, John S.; DASGUPTA, Bireshwar; REDDY, Kotha Rathnakar; RAJA, Thiruvenkadam; (0 pag.)WO2020/6018; (2020); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.110256-15-0,5-Cyclopropylisoxazole-3-carboxylic acid,as a common compound, the synthetic route is as follows.

A suspension of 5-cyclopropylisoxazole-3-carboxylic acid (5.00 g, 32.7 mmol) in DCM (30 mL) was treated sequentially with oxalyl chloride (7.15 mL, 81.6 mmol) and DMF (30 muL, 32.7 mmol). The reaction mixture was stirred for 1.5 h at RT, and then concentrated. The resulting residue was suspended in THF (65.3 mL), cooled to 0 C, and then treated with malononitrile (2.59 g, 39.2 mmol) and DIPEA (14.3 mL, 81.6 mmol). After stirring the reaction mixture for 48 h at 0 C, and 2 h at RT, dimethyl sulfate (9.36 mL, 98.0 mmol) was added. The resulting reaction mixture was stirred at 70 C until LCMS indicated complete consumption of starting materials. The mixture then was cooled to RT, and diluted with water (50 mL). The aqueous mixture was extracted with EtOAc. The combined organic extracts were concentrated. The resulting residue was purified by silica chromatography (0-20% EtOAc in hexanes) to afford the title compound (2.27 g, 32%)., 110256-15-0

The synthetic route of 110256-15-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ARRAY BIOPHARMA INC.; BLAKE, James F.; DAI, Donghua; HAAS, Julia; JIANG, Yutong; KOLAKOWSKI,, Gabrielle R.; METCALF, Andrew T.; MORENO, David A.; PRIGARO, Brett; REN, Li; (330 pag.)WO2019/143991; (2019); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

110256-15-0, 5-Cyclopropylisoxazole-3-carboxylic acid is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of 5-cyclopropylisoxazole-3-carboxylic acid (300 mg, 1.9 mmol) in DMF (3 ml), was added HATU (1.1 17 g, 2.9 mmol). The reaction mixture was stirred for 20 min at room temperature. After being cooled to 0 C 1 ,4-dimethylpyrrolidin-3 -amine (250 mg, 2.1 mmol) and DIPEA (380 mg, 2.9 mmol) were added to the reaction mixture. It was stirred at room temperature for 2 hrs. Completion of the reaction was confirmed by TLC. After completion, water (30 mL) was added and the product was extracted with ethyl acetate (2 x 30 mL). The combined organic layer was washed with brine, dried over sodium sulfate and concentrated under vacuum to get the crude product which was purified by column chromatography using 1% MeOH in DCM. Distillation of the pure fractions afforded 392 mg of a mixture of diastereomers and enantiomers. The cis and trans isomers were separated by chiral prep. HPLC using 0.1% diethyamine in n- Heptane: IPA as the mobile phase. Evaporation of pure fractions afforded pure diastereomers. Yields of the isomers were 28 mg, 5.73 %) and (54 mg, 11.06 %). The NMR spectra and LC/MS of the isomers were 1H NMR (400 MHz, MeOD): delta 6.39 (s, 1H), 4.71-4.65 (m, 1H), 3.12 (dd, J = 7.2, 10.4 Hz, 1H), 2.98-2.94 (dd, J = 7.6, 9.2 Hz, 1H), 2.60-2.51 (m, 1H), 2.41 (s, 3H), 2.28 (t, J = 9.2 Hz, 1H), 2.21-2.14 (m, 1H), 1.18- 1.13 (m, 2H), 1.00-0.98 (m, 5H): LCMS: m/z = 249.9 [M+H]+, and 1H NMR (400 MHz, MeOD): delta 6.38 (s, 1H), 4.16-4.12 (m, 1H), 3.02 (dd, J = 7.6, 8.8 Hz, 1H), 2.88 (dd, J = 7.6,10.4 Hz, 1H), 2.70 (dd, J = 5.2, 10 Hz, 1H), 2.39 (s, 3H), 2.28-2.15 (m, 3H), 1.18- 1.12 (m, 5H), 1.00-0.97 (m, 2H); LCMS: m/z = 250.40 [M+H]+., 110256-15-0

The synthetic route of 110256-15-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; EPIZYME, INC.; FOLEY, Megan Alene Cloonan; KUNTZ, Kevin Wayne; MITCHELL, Lorna Helen; MUNCHHOF, Michael John; HARVEY, Darren Martin; (151 pag.)WO2016/40504; (2016); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.110256-15-0,5-Cyclopropylisoxazole-3-carboxylic acid,as a common compound, the synthetic route is as follows.

In a 100-mL round-bottom flask 5 -cyclopropylisoxazole-3 -carboxylic acid (100 mg, 0.65 mmol, 1.00 equiv), tert-butyl N-[(lr,4r)-4-aminocyclohexyl]carbamate (154 mg, 0.72 mmol, 1.10 equiv) and TEA (198 mg, 1.96 mmol, 3.00 equiv) were dissolved in 10 ml dichloromethane, then HATU (496 mg, 1.31 mmol, 2.00 equiv) was added to the solution. The resulting solution was stirred overnight at room temperature. The mixture was then concentrated under vacuum. The residue was purified on a silica gel column with ethyl acetate/petroleum ether (4: 1). This resulted in 210 mg (92%) tert-butyl (lr,4r)- 4-(5 -cyclopropylisoxazole-3 -carboxamido)cyclohexylcarbamate as a white solid. LCMS (method A, ESI): RT=1.48 min, m/z =294.0 [M-56]+.

110256-15-0, The synthetic route of 110256-15-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; EPIZYME, INC.; CHESWORTH, Richard; FOLEY, Megan Alene Cloonan; KUNTZ, Kevin Wayne; MITCHELL, Lorna Helen; PETTER, Russell C.; SCHWARTZ, Carl Eric; (62 pag.)WO2016/40511; (2016); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

110256-15-0, 5-Cyclopropylisoxazole-3-carboxylic acid is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of 5-cyclopropylisoxazole-3-carboxylic acid (300 mg, 1.9 mmol) in DMF (3 ml), was added HATU (1.1 17 g, 2.9 mmol). The reaction mixture was stirred for 20 min at room temperature. After being cooled to 0 C 1 ,4-dimethylpyrrolidin-3 -amine (250 mg, 2.1 mmol) and DIPEA (380 mg, 2.9 mmol) were added to the reaction mixture. It was stirred at room temperature for 2 hrs. Completion of the reaction was confirmed by TLC. After completion, water (30 mL) was added and the product was extracted with ethyl acetate (2 x 30 mL). The combined organic layer was washed with brine, dried over sodium sulfate and concentrated under vacuum to get the crude product which was purified by column chromatography using 1% MeOH in DCM. Distillation of the pure fractions afforded 392 mg of a mixture of diastereomers and enantiomers. The cis and trans isomers were separated by chiral prep. HPLC using 0.1% diethyamine in n- Heptane: IPA as the mobile phase. Evaporation of pure fractions afforded pure diastereomers. Yields of the isomers were 28 mg, 5.73 %) and (54 mg, 11.06 %). The NMR spectra and LC/MS of the isomers were 1H NMR (400 MHz, MeOD): delta 6.39 (s, 1H), 4.71-4.65 (m, 1H), 3.12 (dd, J = 7.2, 10.4 Hz, 1H), 2.98-2.94 (dd, J = 7.6, 9.2 Hz, 1H), 2.60-2.51 (m, 1H), 2.41 (s, 3H), 2.28 (t, J = 9.2 Hz, 1H), 2.21-2.14 (m, 1H), 1.18- 1.13 (m, 2H), 1.00-0.98 (m, 5H): LCMS: m/z = 249.9 [M+H]+, and 1H NMR (400 MHz, MeOD): delta 6.38 (s, 1H), 4.16-4.12 (m, 1H), 3.02 (dd, J = 7.6, 8.8 Hz, 1H), 2.88 (dd, J = 7.6,10.4 Hz, 1H), 2.70 (dd, J = 5.2, 10 Hz, 1H), 2.39 (s, 3H), 2.28-2.15 (m, 3H), 1.18- 1.12 (m, 5H), 1.00-0.97 (m, 2H); LCMS: m/z = 250.40 [M+H]+., 110256-15-0

The synthetic route of 110256-15-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; EPIZYME, INC.; FOLEY, Megan Alene Cloonan; KUNTZ, Kevin Wayne; MITCHELL, Lorna Helen; MUNCHHOF, Michael John; HARVEY, Darren Martin; (151 pag.)WO2016/40504; (2016); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.110256-15-0,5-Cyclopropylisoxazole-3-carboxylic acid,as a common compound, the synthetic route is as follows.

A suspension of 5-cyclopropylisoxazole-3-carboxylic acid (5.00 g, 32.7 mmol) in DCM (30 mL) was treated sequentially with oxalyl chloride (7.15 mL, 81.6 mmol) and DMF (30 muL, 32.7 mmol). The reaction mixture was stirred for 1.5 h at RT, and then concentrated. The resulting residue was suspended in THF (65.3 mL), cooled to 0 C, and then treated with malononitrile (2.59 g, 39.2 mmol) and DIPEA (14.3 mL, 81.6 mmol). After stirring the reaction mixture for 48 h at 0 C, and 2 h at RT, dimethyl sulfate (9.36 mL, 98.0 mmol) was added. The resulting reaction mixture was stirred at 70 C until LCMS indicated complete consumption of starting materials. The mixture then was cooled to RT, and diluted with water (50 mL). The aqueous mixture was extracted with EtOAc. The combined organic extracts were concentrated. The resulting residue was purified by silica chromatography (0-20% EtOAc in hexanes) to afford the title compound (2.27 g, 32%)., 110256-15-0

The synthetic route of 110256-15-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ARRAY BIOPHARMA INC.; BLAKE, James F.; DAI, Donghua; HAAS, Julia; JIANG, Yutong; KOLAKOWSKI,, Gabrielle R.; METCALF, Andrew T.; MORENO, David A.; PRIGARO, Brett; REN, Li; (330 pag.)WO2019/143991; (2019); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

110256-15-0, 5-Cyclopropylisoxazole-3-carboxylic acid is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

[0267] To a stirred solution of 5-cyclopropylisoxazole-3-carboxylic acid (0.750 g, 4.90 mmol) in DCM (5 ml) was added oxalyl chloride (1.68 ml, 19.60 mmol) and 2 drops of DMF. The reaction was stirred at RT 2 hr. After complete consumption of starting material, the solvent was removed under reduced pressure to obtain 5-cyclopropylisoxazole-3-carbonyl chloride as a residue (0.6 g, crude). The material was used without further purification., 110256-15-0

110256-15-0 5-Cyclopropylisoxazole-3-carboxylic acid 1092113, aIsoxazoles compound, is more and more widely used in various fields.

Reference£º
Patent; EPIZYME, INC.; FOLEY, Megan Alene Cloonan; KUNTZ, Kevin Wayne; MILLS, James Edward John; MITCHELL, Lorna Helen; MUNCHHOF, Michael John; HARVEY, Darren Martin; (208 pag.)WO2016/40498; (2016); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

110256-15-0, 5-Cyclopropylisoxazole-3-carboxylic acid is a Isoxazoles compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Step 2: Synthesis of (2S)-tert-butyl 4-(5-cyclopropylisoxazole-3-carboxamido)-2- methylpiperidine-1-carboxylate [0269] Into a 1L round-bottom flask purged and maintained with an inert atmosphere of nitrogen was placed dichloromethane (500 mL), HOBT (15 g, 111.01 mmol, 1.53 equiv), EDCI (20 g, 104.33 mmol, 1.44 equiv), 5-cyclopropyl-1,2-oxazole-3-carboxylic acid (13.3 g, 86.85 mmol, 1.20 equiv) and tert-butyl (2S)-4-amino-2-methylpiperidine-1- carboxylate (15.5 g, 72.33 mmol, 1.00 equiv).Then triethylamine (36 g, 355.77 mmol, 4.92 equiv) was added dropwise. The resulting solution was stirred for 2 hours at 25oC. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 500 mL of ethyl acetate. The resulting mixture was washed with 3×500 mL of water. The residue was purified on a silica gel column with ethyl acetate/petroleum ether (1:10). This resulted in 14 g (55%) of tert-butyl (2S)-4-(5-cyclopropyl-1,2-oxazole-3-amido)-2- methylpiperidine-1-carboxylate as light yellow oil. LCMS (method A, ESI): RT=2.05 min, m/z =350.2 [M+H]+. Step 3: Synthesis of tert-butyl (2S,4S)-4-(5-cyclopropyl-1,2-oxazole-3-amido)-2- methylpiperidine-1-carboxylate and tert-butyl (2S,4R)-4-(5-cyclopropyl-1,2-oxazole-3- amido)-2-methylpiperidine-1-carboxylate [0270] The crude product was purified by Chrial-HPLC with the following conditions: Column name: CHIRALPAK AD-H, 4.6*150mm,5um,Co-Solvent: EtOH(0.1%DEA), %Co-Solvent: Hexane,25.000, Detector: 220nm. The resulting solution was concentrated under vacuum. This resulted in 9.8 g (70%) of tert-butyl (2S,4S)-4-(5-cyclopropyl-1,2- oxazole-3-amido)-2-methylpiperidine-1-carboxylate as white solid. 1H-NMR (400 MHz, DMSO): 8.54-8.52 (m, 1H), 6.47 (s, 1H), 3.94-3.87(m, 2H), 3.57-3.53(m, 1H), 3.32- 3.26(m, 1H), 2.20-2.16(m, 1H), 1.80-1.63(m, 4H), 1.39(s, 9H), 1.16-1.15(m, 3H), 1.10- 1.06(m, 2H), 0.93-0.89(m, 2H) ppm. And 3.3 g (24%) of tert-butyl (2S,4R)-4-(5- cyclopropyl-1,2-oxazole-3-amido)-2-methylpiperidine-1-carboxylate as a light yellow solid. 1H-NMR (400 MHz, DMSO): 8.54-8.52 (m, 1H), 6.46 (s, 1H), 4.54-4.30(m, 1H), 4.28-4.04(m, 1H), 4.00-3.68(m, 1H), 3.10-2.70(m, 1H), 2.19-2.15(m, 1H), 1.76-1.73(m, 1H), 1.63-1.59(m, 2H), 1.39-1.35(m, 10H), 1.13-1.08(m, 5H),1.00-0.82(m, 2H) ppm.

110256-15-0, 110256-15-0 5-Cyclopropylisoxazole-3-carboxylic acid 1092113, aIsoxazoles compound, is more and more widely used in various fields.

Reference£º
Patent; EPIZYME, INC.; MITCHELL, Lorna Helen; BELL, Andrew Simon; CHESWORTH, Richard; FOLEY, Megan Alene Cloonan; KUNTZ, Kevin Wayne; MILLS, James Edward John; MUNCHHOF, Michael John; (375 pag.)WO2016/40515; (2016); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.110256-15-0,5-Cyclopropylisoxazole-3-carboxylic acid,as a common compound, the synthetic route is as follows.

To a solution of cis tert-butyl 4-amino-2-methylpiperidine-1-carboxylate (1 g, 4.67 mmol) and DIPEA (2.44 ml, 14 mmol) in DMF (25ml) was added 5-cyclopropyl- 1,2-oxazole-3-carboxylic acid (0.86 g, 5.6 mmol) followed by HATU (2.31 g, 6.07 mmol). The reaction was stirred at rt. LCMS analysis after ~1h showed a trace of SM and mainly product (72%, 1.33min, MNa+.=371.95). The reaction was poured into water (100ml) and the product was extracted with EtOAc (3x50ml). The combined organic layers were washed with water (2x50ml), brine (50ml), dried over Na2SO4, filtered and concentrated. The red oily residue was purified by Isolera over SiO2 (100g), eluting with a gradient of EtOAc in heptane from 5 to 50 % to yield 1.55 g (95%) of the amide as an amber viscous. TLC (25% EtOAc in Hept), rf:0.30.1H NMR (500 MHz, Chloroform-d) 6.85 (d, J = 6.8 Hz, 1H), 6.31 (s, 1H), 4.21 (hept, J = 6.8, 6.1 Hz, 2H), 3.85 (ddd, J = 14.0, 5.5, 3.1 Hz, 1H), 3.13 (ddd, J = 14.3, 11.9, 3.9 Hz, 1H), 2.06 (ddd, J = 8.4, 4.9, 3.4 Hz, 1H), 2.02- 1.91 (m, 2H), 1.74- 1.66 (m, 2H), 1.45 (s, 9H), 1.25 (d, J = 7.2 Hz, 3H), 1.13- 1.08 (m, 2H), 1.00- 0.94 (m, 2H). LCMS analysis (METCR1673 Generic 2 minutes), 100%, 1.33min, [MNa]+.=372.00.

110256-15-0, As the paragraph descriping shows that 110256-15-0 is playing an increasingly important role.

Reference£º
Patent; EPIZYME, INC.; MITCHELL, Lorna Helen; BELL, Andrew Simon; CHESWORTH, Richard; FOLEY, Megan Alene Cloonan; KUNTZ, Kevin Wayne; MILLS, James Edward John; MUNCHHOF, Michael John; (375 pag.)WO2016/40515; (2016); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.110256-15-0,5-Cyclopropylisoxazole-3-carboxylic acid,as a common compound, the synthetic route is as follows.

Into a 250-mL round-bottom flask purged and maintained with an inert atmosphere of nitrogen was placed tert-butyl 4-amino-2-benzylpiperidine-1-carboxylate (5 g, 17.22 mmol, 1.00 equiv), dichloromethane (100 mL), TEA (8.707 g, 86.05 mmol, 5.00 equiv), 5-cyclopropyl-1,2-oxazole-3-carboxylic acid (3.957 g, 25.84 mmol, 1.50 equiv), HATU (19.655 g, 51.69 mmol, 3.00 equiv). The resulting solution was stirred overnight at room temperature. The resulting mixture was concentrated under vacuum. The resulting solution was diluted with 200 mL of EA. The resulting mixture was washed with 3×200 mL of brine (sat.). The organic phase was collected and dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was applied onto a silica gel column with ethyl acetate/petroleum ether (1:10). The collected fractions were combined and concentrated under vacuum. The crude product 2.9 g was purified by Prep-SFC with the following conditions (prep SFC 350-2): Column, Chiralpak AD-H, 5x25cm, 5um; mobile phase, CO2(70%), IPA(30%) and DCM/MeOH=1/3:100 ; Detector, uv 210nm yielding two fractions: first peak – cis enantiomers 1.7 g, second peak trans enantiomers 0.6 g. [0279] These products were further purified by SFC. The cis mixtures were purified by Prep-SFC with the following conditions (prep SFC 350-2): Column, Chiralpak AS-H, 5*25cm, 5um; mobile phase, CO2 (70%), IPA (30%) and MeOH (50%); Detector, uv 210nm. This resulted in 820 mg of (2R,4R)-tert-butyl 2-benzyl-4-(5- cyclopropylisoxazole-3-carboxamido)piperidine-1-carboxylate as yellow oil and 870 mg of(2S,4S)-tert-butyl 2-benzyl-4-(5-cyclopropylisoxazole-3-carboxamido)piperidine-1- carboxylate as yellow oil. (2R,4R)-tert-butyl 2-benzyl-4-(5-cyclopropylisoxazole-3- carboxamido)piperidine-1-carboxylate: 1H-NMR (300 MHz, CD3Cl) : 7.26-7.17(m, 5H), 6.88 (d, J = 6.9 Hz, 1H), 6.32(d, J = 0.6 Hz, 1H), 4.38-4.28 (m, 1H), 4.27-4.16 (m, 1H), 4.09-3.98(m, 1H), 3.18-2.99 (m, 2H), 2.82-2.75 (m,1H), 2.12-1.98(m, 2H), 1.91- 1.66 (m, 3H), 1.37(d, J = 2.7 Hz, 9H), 1.18-1.09 (m, 2H), 1.02-0.92 (m, 2H) ppm. LCMS (method A, ESI): RT =1.59 min, m/z =326.0 [M-Boc+H]+. (2S,4S)-tert-butyl 2-benzyl-4- (5-cyclopropylisoxazole-3-carboxamido)piperidine-1-carboxylate: 1H-NMR (300 MHz, CD3Cl) : 7.26-7.17(m, 5H), 6.88(d, J = 6.9 Hz, 1H), 6.32(d, J = 0.6Hz, 1H), 4.38-4.28 (m, 1H), 4.27-4.16 (m, 1H), 4.09-3.98(m, 1H), 3.18-2.99 (m, 2H), 2.82-2.75 (m, 1H), 2.12-1.98(m, 2H), 1.91-1.66 (m, 3H), 1.37(d, J = 2.7 Hz, 9H), 1.18-1.09(m, 2H), 1.02- 0.92(m, 2H) ppm. LCMS (method A, ESI): RT =1.59 min, m/z = 326.0 [M-Boc+H]+. [0280] The trans mixture was purified by Prep-SFC with the following conditions (prep SFC 350): Column, Phenomenex Lux 5u Cellulose-4250*50mm00G-4491-V0- AX664184-1; mobile phase, CO2(50%) and MeOH(50%) ,Detector, uv 220 nm. This resulted in 250 mg of (2S,4R)-tert-butyl 2-benzyl-4-(5-cyclopropylisoxazole-3- carboxamido)piperidine-1-carboxylate as yellow oil and 260 mg of (2R,4S)-tert-butyl 2- benzyl-4-(5-cyclopropylisoxazole-3-carboxamido)piperidine-1-carboxylate as yellow oil. (2S,4R)-tert-butyl 2-benzyl-4-(5-cyclopropylisoxazole-3-carboxamido)piperidine-1- carboxylate: 1H-NMR (300 MHz, CD3Cl) : 7.26-7.17(m, 5H), 6.88(d, J = 6.9 Hz, 1H), 6.32(s, 1H), 4.81-3.91 (m, 3H), 3.08(t, J = 13.5 Hz, 1H), 2.96-2.81(m, 2H), 2.11-2.02(m, 2H), 1.95(d, J = 10.5 Hz, 1H), 1.52-1.22(m, 11H), 1.15-1.05(m, 2H), 1.02-0.92(m, 2H) ppm. LCMS (method A, ESI): RT = 1.58 min, m/z = 448.0 [M+Na]+. (2R,4S)-tert-butyl 2-benzyl-4-(5-cyclopropylisoxazole-3-carboxamido)piperidine-1-carboxylate: 1H-NMR (300 MHz, CD3Cl) : 7.26-7.17(m, 5H), 6.88(d, J = 6.9 Hz, 1H), 6.32(s, 1H), 4.81-3.91 (m, 3H), 3.08(t, J = 13.5 Hz, 1H), 2.96-2.81(m, 2H), 2.11-2.02(m, 2H), 1.95(d, J = 10.5 Hz, 1H), 1.52-1.22(m, 11H), 1.15-1.05(m, 2H), 1.02-0.92(m, 2H) ppm. LCMS (method A, ESI): RT = 1.58 min, m/z = 448.0 [M+Na]+.

110256-15-0, 110256-15-0 5-Cyclopropylisoxazole-3-carboxylic acid 1092113, aIsoxazoles compound, is more and more widely used in various fields.

Reference£º
Patent; EPIZYME, INC.; MITCHELL, Lorna Helen; BELL, Andrew Simon; CHESWORTH, Richard; FOLEY, Megan Alene Cloonan; KUNTZ, Kevin Wayne; MILLS, James Edward John; MUNCHHOF, Michael John; (375 pag.)WO2016/40515; (2016); A1;,
Isoxazole – Wikipedia
Isoxazole | C3H3NO – PubChem